NovaBay Other Liab from 2010 to 2024

NBY Stock  USD 0.68  0.04  5.56%   
NovaBay Pharmaceuticals Other Liabilities yearly trend continues to be fairly stable with very little volatility. Other Liabilities is likely to outpace its year average in 2024. During the period from 2010 to 2024, NovaBay Pharmaceuticals Other Liabilities regression line of annual values had r-squared of  0.50 and arithmetic mean of  5,832,636. View All Fundamentals
 
Other Liabilities  
First Reported
2006-12-31
Previous Quarter
342 K
Current Value
3.2 M
Quarterly Volatility
1.9 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NovaBay Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NovaBay Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 229.5 K, Interest Expense of 4.6 M or Other Operating Expenses of 16.9 M, as well as many indicators such as Price To Sales Ratio of 0.0555, Dividend Yield of 0.0 or PTB Ratio of 0.25. NovaBay financial statements analysis is a perfect complement when working with NovaBay Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of NovaBay Pharmaceuticals Correlation against competitors.
For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.

Latest NovaBay Pharmaceuticals' Other Liab Growth Pattern

Below is the plot of the Other Liab of NovaBay Pharmaceuticals over the last few years. It is NovaBay Pharmaceuticals' Other Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NovaBay Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Other Liab10 Years Trend
Slightly volatile
   Other Liab   
       Timeline  

NovaBay Other Liab Regression Statistics

Arithmetic Mean5,832,636
Geometric Mean4,453,613
Coefficient Of Variation67.34
Mean Deviation3,451,163
Median3,957,000
Standard Deviation3,927,870
Sample Variance15.4T
Range11.7M
R-Value0.70
Mean Square Error8.4T
R-Squared0.50
Significance0
Slope618,711
Total Sum of Squares216T

NovaBay Other Liab History

202412.2 M
202311.6 M
202010.1 M
20194.1 M
2018560 K
20172.5 M
2016M

About NovaBay Pharmaceuticals Financial Statements

NovaBay Pharmaceuticals investors use historical fundamental indicators, such as NovaBay Pharmaceuticals' Other Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NovaBay Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Liabilities11.6 M12.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NovaBay Stock Analysis

When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.